Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008.

"Dirucotide has demonstrated the ability to safely affect MS progression in previous studies and we look forward to the results of the Canadian/European trial (MAESTRO-01) in the second half of this year," said Kevin Giese, President and CEO of BioMS Medical. "Our hope is that the results of this trial will confirm that dirucotide is able to significantly slow the progression of MS, specifically in patients with secondary progressive multiple sclerosis."

Currently, BioMS is conducting two clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

        -  MAESTRO-01: On January 22, 2007, BioMS announced that this pivotal
           phase III trial, being conducted in Canada and Western Europe, had
           completed full recruitment of 611 SPMS patients at 47 trial sites
           in ten countries. To date, there have been nine positive safety
           reviews from the Data Safety Monitoring Board (DSMB). The primary
           clinical endpoint for MAESTRO-01 (and MAESTRO-03) is defined as a
           statistically and clinically significant increase in the time to
           progression of the disease as measured by the Expanded Disability
           Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4
           immune response genes.

           On August 13, 2008, the DSMB conducted a scheduled interim
           analysis of efficacy and safety and recommended that the trial
           continue to completion. The interim analysis evaluated the first
           200 patients to complete MAESTRO-01 and assessed the likelihood of
           the study reaching
'/>"/>
SOURCE  BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... May 16, 2013 A new ... models, from Cole-Parmer is designed to meet the ... includes: , The new Cole-Parmer® MS-3400 Centrifuges ... in the lab. They ensure a powerful and ... specimen separation. Their standard four-place swinging buckets hold ...
(Date:5/16/2013)... Kitware , a leading ... new Phase II SBIR funding from the U.S. ... an open-source, high performance computing (HPC) simulation and ... researchers to select only the toolkits and applications ... or analysis tasks. , Manufacturers increasingly rely ...
(Date:5/16/2013)... 2013  The registration deadline has been extended until ... 2013 National Conference, the premier conference for bioscience financial ... the Hilton San Diego Bayfront. "We ... and want to make sure as many people as ... Brandi Roberts , Chief Financial Officer of Mast ...
(Date:5/16/2013)... As the weather warms, women everywhere are waiting for the ... make a statement with fashion, many change their makeup to ... mixes makeup and sweat to produce, and increase acne breakouts. ... warmer months, Adult Acne treatment , Probiotic Action shares ... to deter breakouts. , Recently, an article from ...
Breaking Biology Technology:Cole-Parmer Offers Enhanced Selection of Centrifuges 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2
... opportunities noted that the FDA sees radio frequency identification ... integrity of the U.S. drug supply. RFID allows pharmaceutical ... chain of distribution from manufacturer to pharmacy. , ... an initiative to improve identification ...
... College in Eau Claire are offering up to eight ... firms or organizations with an economic interest in nanotechnology ... comprise each of five teams with project completion by ... the purchase of an electron microscope are the best ...
... Fiserv, Inc. announced strong earnings for the third ... for the third quarter of 2005 was $0.58 per share, ... 2004. Processing and services revenues were $925.3 million, an increase ... "We are also very excited about our recent acquisitions, including ...
Cached Biology Technology:RFID medical devices - Opportunities and challenges 2RFID medical devices - Opportunities and challenges 3RFID medical devices - Opportunities and challenges 4
(Date:5/18/2013)... 18, 2013) Research presented today at Digestive Disease ... with findings about the impact of coffee on autoimmune ... While coffee consumption recently has been associated with reduced ... a few more cups of java each month also ... disease. Researchers at the Mayo Clinic, Rochester, MN, linked ...
(Date:5/17/2013)... noise of the South, but the night belongs to the ... heavy from the humidity and the sounds of wildlife. ... frogs, toads and salamanders, is the center of amphibian biodiversity ... the auditorium for their symphonic choruses, the scientists of the ... have front-row seats. , Amphibians, which rely on ...
(Date:5/17/2013)... 2013, Shenzhen, China---- Why Tibetan antelope can live ... In a collaborative research published in Nature ... other institutes provide evidence that some genetic factors ... harsh highland environments. The data in this work ... mechanisms and the biology of other ruminant species. ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2
... all go a little gooey, but it,s not turning mums, ... Australian National University. The study conducted by the ... that despite fears mothers may have that pregnancy affects their ... true. The findings have been released as part of Mental ...
... CT Contrary to conventional wisdom, tropical plant and animal ... may be threatened by global warming, according to an article ... in this week,s (Oct. 10) issue of Science ... the geographical ranges of well-studied bird, butterfly, and plant species ...
... of patients with compromised immune systems has grown ... unique set of healthcare solutions that take into ... immune suppression to the individual patient,s nutritional status. ... of the Immunocompromised Host,examines a wide range of ...
Cached Biology News:Pregnancy not turning minds to mush: Study 2Tropical rainforest and mountain species may be threatened by global warming 2Text focuses on diagnosing infections in immunocompromised patients 2